Open-label Rollover Study to Evaluate Long-Term Safety in Subjects with Metastatic Solid Tumors that are Benefiting from Continuation of Therapy with Sacituzumab Govitecan

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-505336-34-00

Acronym

IMMU-132-14

Enrollment

Registered

2023-10-02

Start date

2020-10-08

Completion date

2024-10-17

Last updated

2024-10-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Metastatic solid tumors

Brief summary

The primary endpoints are as follows: Percentage of participants experiencing any AE., Percentage of participants experiencing any SAE., Percentage of participants experiencing any laboratory abnormality.

Interventions

DRUGTrodelvy 200 mg powder for concentrate for solution for infusion

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
The primary endpoints are as follows: Percentage of participants experiencing any AE., Percentage of participants experiencing any SAE., Percentage of participants experiencing any laboratory abnormality.	—

Countries

Belgium, France, Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026